![Maria Pascual](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Maria Pascual
Algemeen Adviseur bij TIGENIX NV
Actieve functies van Maria Pascual
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TIGENIX NV | Algemeen Adviseur | - | - |
Loopbaan van Maria Pascual
Eerdere bekende functies van Maria Pascual
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Asociacion De Empresas Biotecnologicas
![]() Asociacion De Empresas Biotecnologicas BiotechnologyHealth Technology Asociacion De Empresas Biotecnologicas operates as a Spanish biotechnology company. The private company is based in Madrid, Spain. | Directeur/Bestuurslid | 01-01-2011 | 01-01-2015 |
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Algemeen Adviseur | 01-01-2005 | 01-01-2013 |
Genetrix SL
![]() Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 | 01-01-2005 |
Leids Universitair Medisch Centrum
![]() Leids Universitair Medisch Centrum Hospital/Nursing ManagementHealth Services Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands. | Corporate Officer/Principal | 01-01-1999 | 01-01-2001 |
Opleiding van Maria Pascual
University of Granada | Undergraduate Degree |
Consejo Superior de Investigaciones Científicas | Doctorate Degree |
Universitat Autònoma de Barcelona | Graduate Degree |
Statistieken
Internationaal
Spanje | 7 |
België | 2 |
Nederland | 2 |
Operationeel
General Counsel | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 4 |
Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
TiGenix NV
![]() TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
Asociacion De Empresas Biotecnologicas
![]() Asociacion De Empresas Biotecnologicas BiotechnologyHealth Technology Asociacion De Empresas Biotecnologicas operates as a Spanish biotechnology company. The private company is based in Madrid, Spain. | Health Technology |
Genetrix SL
![]() Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | Health Technology |
Leids Universitair Medisch Centrum
![]() Leids Universitair Medisch Centrum Hospital/Nursing ManagementHealth Services Leids Universitair Medisch Centrum provides medical research, patient care, training, and education. The firm offers fundamental medical and applied clinical research. The company was founded in 1996 and is headquartered in Leiden, the Netherlands. | Health Services |
- Beurs
- Insiders
- Maria Pascual
- Ervaring